A provider can offer testosterone treatment without telling you, in a headline, exactly which medicine it intends to prescribe. The hormone name is only one part of the answer. An FDA-approved finished product and a compounded preparation containing testosterone do not have the same regulatory status.
We checked FDA guidance and product information on September 22, 2026. This guide explains the distinction so you can ask more precise questions. It does not decide which medicine is appropriate for an individual or suggest that every compounded prescription is unsuitable.
KEEP IN MIND
The useful bits.
- Compounded medicines are not FDA-approved.
- Pharmacy licensure, ingredient identity, and finished-product approval are different matters.
- Ask what need the proposed formulation addresses and follow its own instructions.
Approval belongs to a particular finished product
FDA approval concerns a defined product with specific labeling and supporting evidence. Depo-Testosterone is a named testosterone cypionate injection; AndroGel 1.62% is a particular topical product. Those labels do not establish that every injection, cream, or gel with testosterone is the same approved medicine.
Ask for the exact name, formulation, route, and manufacturer where relevant. The injection-versus-gel guide explains why practical instructions also depend on the product. A familiar ingredient or similar-sounding brand should not be used to transfer approval, dosing, or safety claims to a different preparation.
Sources: FDA: understanding the risks of compounded drugs · Pfizer: Depo-Testosterone prescribing information · DailyMed: AndroGel 1.62% prescribing information
Compounding is a different pathway
Compounding involves preparing a medicine to meet a patient’s needs, such as when an approved product cannot appropriately meet a particular requirement. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before marketing through the same approval process used for approved finished medicines.
That distinction supports a specific clinical question: what need does this compounded preparation address for me? It does not support a universal conclusion that compounding is always better because it is personalized, or always inappropriate because it lacks product approval. Ask the prescriber to explain the actual rationale.
A licensed pharmacy does not make the preparation FDA-approved
Pharmacy licensure and FDA product approval are different concepts. A provider may accurately describe using a licensed pharmacy while prescribing a compounded preparation. Request the dispensing pharmacy’s name, contact information, and the product instructions so you know who is responsible for preparation and who can answer dispensing questions.
If a website does not identify the pharmacy for your prescription, leave that detail unverified. Our TRT Nation review distinguishes the provider’s compounding-pharmacy statement from independent product verification. Broad descriptions such as pharmacy-grade do not answer every question about a specific finished medicine.
Personalization is not proof of better outcomes
A clinician may adjust care for legitimate reasons, but a marketing word such as tailored or bioidentical is not comparative clinical evidence. Ask what improvement is expected, how it will be assessed, and what uncertainties remain. The need for a confirmed diagnosis and an appropriate monitoring plan still applies.
Do not assume that an unusual concentration, extra ingredient, or nonstandard combination reduces risk. The clinician should explain why each part is being considered. The testing guide covers the diagnostic foundation that comes before choosing a formulation or a subscription.
Sources: FDA: understanding the risks of compounded drugs · Endocrine Society: testosterone therapy clinical guidance
Instructions need to match the product you actually receive
Different routes and formulations have different handling requirements. A topical gel can raise transfer concerns for other people; an injectable product raises different administration and supply questions. Ask the prescriber and pharmacist to explain the label supplied with your own medicine rather than following instructions intended for another formulation.
If the package, concentration, device, or directions differ from what you expected, contact the clinical team or pharmacy before improvising. This guide does not provide a dosing conversion. Neither an online comparison nor another person’s prescription can establish how your medicine should be used.
Sources: Pfizer: Depo-Testosterone prescribing information · DailyMed: AndroGel 1.62% prescribing information · FDA: understanding the risks of compounded drugs
Keep the evidence and the cost on separate lines
A lower price does not establish an equivalent product, and a higher price does not prove greater safety. Compare the actual medication, clinical support, laboratory arrangements, and financial term. Ask how blood pressure, blood counts, symptoms, and adverse effects will be reviewed if treatment proceeds.
The cost planner helps with arithmetic once the quote is clear. The monitoring checklist covers continuing responsibilities. A transparent decision records both what the proposed product is and why the clinician believes it fits your needs, without replacing medical judgment with promotional language.
Sources: FDA: understanding the risks of compounded drugs · FDA: 2025 testosterone labeling and blood pressure changes · Endocrine Society: testosterone therapy clinical guidance
Sources you can check
Provider pages describe commercial offers. Medical references provide context. Checked September 22, 2026; prices and availability can change.
Educational information for adults, not a diagnosis or treatment plan. Discuss symptoms and treatment decisions with a licensed clinician. Do not change a prescription based on this article.